Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 50 a 75 de 345
Resumen de: EP4822355A2
0001 Disclosed herein are methods based on the identification of reduced Hsp70 levels in PBMC samples serving as a biomarker for diseases presenting with a reduced level of Hsp70, such as lysosomal storage diseases, neurodegenerative diseases and muscular diseases.
Resumen de: WO2025118073A1
The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Resumen de: EP4821941A1
The present invention provides a cerebrum-targeting peptide including an amino acid sequence represented by SEQ ID NO: 1, and a method for screening a peptide that binds to a target cell in a non-human organism, comprising contacting a peptide library consisting of 7-amino acid peptides with a target cell to recover a group of peptides that bind to the target cell to obtain a peptide population that binds to the target cell, and selecting, from the peptide population, a peptide consisting of an amino acid sequence that is identical to a portion of a protein expressed in the non-human organism and that is also identical to a portion of a protein constituting a virus, as a peptide that binds to the target cell.
Resumen de: WO2026212310A1
The present invention relates to a degenerative brain disease model and a method for constructing same and, more specifically, to a disease modeling technology for reproducing non-genetic (sporadic) Alzheimer's disease and cerebral amyloid angiopathy (CAA), which account for the majority of actual patients on the basis of a V-NAMO platform without relying on genetic mutations. Through a combined exposure strategy of amyloid beta oligomers in consideration of the characteristics of a scaffold, pathology in which amyloid plaques accumulate along actual vascular walls and the neurovascular unit is damaged is precisely implemented in vitro, thereby providing an innovative platform for research on mechanisms of degenerative brain diseases and preclinical efficacy evaluation of new drug candidates.
Resumen de: US20260306439A1
The present disclosure is directed to methods of promoting phagocytosis, particularly the phagocytic activity of microglia via activation of triggering receptor expressed on myeloid cells 2 (TREM2). The present disclosure is also directed to methods of activating TREM2 in a cell, particularly a neuronal cell exhibiting an accumulation of a pathogenic protein. The present disclosure is directed to detecting an effect of a compound on the TREM2 activity as well.
Resumen de: US20260309723A1
0000 Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: WO2026211690A1
The present invention addresses the problem of providing a method, a kit, and a biomarker for assisting diagnosis of schizophrenia or depression, and providing a method, a kit, and a biomarker for assisting differentiation from schizophrenia or depression. The present invention provides a method for assisting diagnosis of schizophrenia or depression, wherein the method comprises detecting cells having MS4A3 contained in a test sample.
Resumen de: WO2026209799A1
The present application discloses a method of monitoring and/or determining the responsiveness of a subject's eye having capillary retinal perfusion dysfunction, to an administration of a first dose of Annexin A5 to the subject, wherein the method comprises assessing the health of the eye and/or assessing total plasma concentration of phosphatidylserine (PS) at about or within a week, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day, of the administration of the first dose of the Annexin A5 to the subject. These methods permit the rapid stratification of subjects into appropriate treatment groups, and the early onset of a treatment regime that is therapeutically appropriate to the subject.
Resumen de: US20260306430A1
Compositions, kits, and methods are disclosed for nutritional neurometabolic support and improved gut health using bioidentical D-beta-hydroxybutyric acid (D-BHB) to promote neurological wellness, mood stability and adaptive brain function during everyday life and during changes in neurologically acting medication regimens. The compositions comprise a salt-free, ester-free, alcohol-free D-BHB acid formulation optionally configured with vitamin B to raise circulating ketone levels, supply a preferred brain energy substrate, and support intestinal barrier integrity by improving tight junction function and reducing paracellular leakiness, thereby influencing gut-brain axis signaling. The compositions optionally incorporate B vitamins with vitamin B6 being a preferred embodiment to complement bioidentical D-BHB by supporting neurotransmitter synthesis and related gut-brain pathways. Kit (701) provides unit dose containers of bioidentical D-BHB, with or without B-vitamin supplementation and optional tapered pharmaceutical doses, together with optional software or AI-based tools configured to capture diet and mood data via smartphone and to generate guidance for nutritional and medication-taper support.
Resumen de: WO2026213047A1
Described herein are methods for analyzing microRNAs (miRNAs) derived from a population of extracellular vesicles (EVs) in a biological sample using next generation sequencing (NGS). The methods comprise isolating the population of EVs from a biological sample obtained from a subject, extracting RNA from the population of EVs, wherein the extracted RNA comprises one or more miRNAs, ligating one or more adapters to the extracted RNA to generate adapter-ligated RNA molecules, reverse transcribing the adapter-ligated RNA molecules to generate a complementary DNA (cDNA) library, amplifying the cDNA library, sequencing the amplified cDNA library using NGS to obtain sequencing reads, and analyzing the sequencing reads by a bioinformatic workflow.
Resumen de: US20260308202A1
Described herein are peptides and pharmaceutical compositions, e.g., for the treatment of inflammation. Further described herein are methods of treating patients for inflammation and/or infection with particularly efficacious treatments depending on the subject's level of fVEGF.
Resumen de: WO2026213448A1
Methods are provided for the high yield and low-cost manufacture of highly pure tau proteins for use as substrates for tau seed amplification assays.
Resumen de: US20260309703A1
The present disclosure describes a diagnostic platform that combines CRISPR/Cas technology with electrochemiluminescence (ECL) or fluorescence detection for highly sensitive and specific identification of disease biomarkers, such as microRNAs and proteins, without the need for complex amplification processes.
Resumen de: US20260309671A1
Various examples are provided related to electrochemical biosensors, systems, and methods of use. A biomarker associated with a disease in a biological fluid sample can be detected by first contacting the biological fluid sample with a working electrode of an electrochemical biosensor. Next, one or more changes in an electronic property of the working electrode resulting from binding of the biomarker to the capture agent can be detected. Then, electrochemical data can be determined based at least in part on the one or more changes in the electronic property of the working electrode detected by the electrochemical biosensor. The electrochemical data can then be input into a machine-learning (ML) model trained to analyze the electrochemical data to determine a risk level associated with the disease. Finally, the risk level associated with the disease can be determined based at least in part on the ML model.
Resumen de: WO2026213117A1
In one aspect, methods for treating a subset of subjects suffering from schizophrenia/schizoaffective disorder exhibiting negative symptoms and/or cognitive deficits that include a) identifying a subject having increased inflammation connected with redox imbalance of olfactory epithelia, and b) treating the identified subject for schizophrenia and/or a schizoaffective disorder. In further aspects, methods of treating subjects with schizophrenia and related psychotic disorders include administration of Nrf2 activators. In further aspects, methods are provided for diagnosing, prognosing, and defining a treatment in response to nasal examination, including Alzheimer's disease and/or cognitive impairment.
Resumen de: US20260309724A1
Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.
Resumen de: AU2025241870A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: WO2026209595A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops Amyloid- Related Imaging Abnormality - Edema (ARIA-E) by determining an amount or a concentration of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in a sample of the subject. Further, the present invention relates to the use of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in the detection of ARIA-E.
Resumen de: US20260308210A1
0000 A polypeptide capable of inhibiting Tau aggregation includes an amino acid sequence sharing between 20% and 99% sequence similarity with a structured core region of a pathological Tau filament, where the polypeptide is capable of binding to an end of a Tau fibril and reducing Tau aggregation or Tau seeding activity. The polypeptide may include an amino acid sequence derived from a microtubule-associated protein such as MAP2 or MAP4. Methods for inhibiting Tau aggregation in a biological sample include contacting the biological sample containing Tau with the polypeptide, where the polypeptide binds to an end of a Tau fibril and reduces Tau aggregation relative to a control sample.
Resumen de: WO2026209593A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of NfL in a sample of the subject. Further, the present invention relates to the use of NfL in the detection of ARIA-E.
Resumen de: WO2026212334A1
The present invention relates to an immunodiagnostic method using multiple biomarkers, which can improve diagnostic efficiency compared to conventional immunodiagnostic devices. The immunodiagnostic method comprises the steps of: setting a reference range for the level of biomarkers; collecting a human-derived sample from a subject to be tested; measuring two or more biomarkers in the sample so as to be individually identifiable, using detection media capable of distinguishing the biomarkers from each other; and selecting a sample in which the measured level of biomarkers falls outside the reference range.
Resumen de: WO2026209594A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of Amyloid-beta 42 (Aβ42) in a sample of the subject. Further, the present invention relates to the use of Aβ42 in the detection of ARIA-E.
Resumen de: US20260309718A1
0000 The present invention covers an in vitro method for evaluating the ability of a compound to disrupt or stabilize an interaction between one or more bait and one or more candidate prey in a eukaryotic cell. In addition, the present invention covers compounds identified by the in vitro method according to any one of the preceding claims, for use as a medicament.
Resumen de: US20260306662A1
0000 Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Nº publicación: US20260306484A1 08/10/2026
Solicitante:
11949098 CANADA INC NUREDCO C/O JEAN I TCHERVENKOV [CA]
11949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
Resumen de: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
BOPI
Sede Electrónica
